Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
In recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS); With the great development of molecular biology, epidermal growth factor receptor-tyrosine kina...
Main Authors: | Shuping XUE, Tingting YU, Yan ZHANG, Li SHAN |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2015-10-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2015.10.10 |
Similar Items
-
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01) -
Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
by: Eun Young Kim, et al.
Published: (2018-12-01) -
Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma
by: Kun QIAN, et al.
Published: (2017-08-01) -
Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
by: Xie Y, et al.
Published: (2021-10-01) -
Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them
by: Yunshu SHI, et al.
Published: (2019-05-01)